Trials / Completed
CompletedNCT00170625
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Multicenter, Prospective Phase-I/II-study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- North Eastern German Society of Gynaecological Oncology · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compatibility of the topotecan therapy in combination with carboplatin.
Detailed description
The aim of the study was to confirm the tolerability of 3-day topotecan therapy in combination with carboplatin in accordance with published data and to investigate the tolerability of continued therapy until disease progression or up to a maximum of 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hycamtin | Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2005-08-01
- First posted
- 2005-09-15
- Last updated
- 2024-11-12
- Results posted
- 2017-02-06
Source: ClinicalTrials.gov record NCT00170625. Inclusion in this directory is not an endorsement.